Mylan Can’t Move Sanofi’s EpiPen Antitrust Suit

Law360, New York (July 13, 2017, 5:28 PM EDT) -- A New Jersey federal judge on Wednesday denied EpiPen maker Mylan’s motion to move to Kansas a lawsuit alleging that it offered rebates to insurers that refused to cover a competing Sanofi-Aventis epinephrine auto-injector.

U.S. District Judge Freda L. Wolfson rejected without comment Mylan Inc.’s contention that shifting the case to Kansas would allow Sanofi’s suit to be consolidated with a series of other class actions from buyers of the EpiPen, also alleging antitrust violations by Mylan.

The suit, filed in April, accused Mylan of sabotaging...
To view the full article, register now.